Crizotinib in the treatment of non‐small cell lung cancer
MUDr. Ondřej Venclíček
Klinika nemocí píicních a tuberkulózy LF MU a FN Brno
Crizotinib is an ALK, ROS1 and MET tyrosine kinase inhibitor approved for the treatment of ALK and ROS1 positive, advanced, non-small cell lung cancer, both in the first line of treatment and in previously treated patients. The following text presents the results of studies that showed the role of crizotinib in the treatment of non-small cell lung cancer, its different molecular targets (ALK, ROS1 and MET), mechanism of action and side effects.
crizotinib, tyrosine kinase inhibitor, non-small cell lung cancer
The full article is only available to subscribers
Become a regular subscriber to our Oncological Review...